Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) Study

AIDS Research and Human Retroviruses

Volumn 26, Issue 6, 2010, Pages 705-709

  Papathanasopoulos, Maria A ^a   Vardas, Eftyhia ^a   Wallis, Carole ^a   Glashoff, Richard ^b   Buttó, Stefano ^c   Poli, Guido ^d,e   Malnati, Mauro ^d   Clerici, Mario ^f   Ensoli, Barbara ^c  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETRAVIRINE; INTEGRASE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; PROTEINASE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTH AFRICA; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; VIROLOGY;

ADULT; CLUSTER ANALYSIS; FEMALE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; SOUTH AFRICA;

EID: 77954195635     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0281     Document Type: Article

References (15)

1. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
2. Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature 2008;455:613-619.
3. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23.
4. Wallis CL, Papathanasopoulos MA, Lakhi S, et al.: Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 2010; 163(2):505-508.
5. Fish M. Hewer R, Wallis CL, et al.: Natural polymorphisms of integrase amongst HIV-1 infected South African patients. AIDS Research and Human Retroviruses (in press).
6. Papathanasopoulos MA, Hunt GM, and Tiemessen C: Review: Evolution and diversity in HIV-1 in Africa. Virus Genes 2003;6:151-163.
7. Parkin NT, Gupta S, Chappey C, and Petropoulos CJ: The K101P and K103R=V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2006;50:351-354.
8. Stoeckli TC, MaWhinney S, Uy J, et al.: Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother 2002;46:4000-4003.
9. Kagan RM, Sista P, Pattery T, Bacheler L, and Schwab DA: Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 2009;23:1602-1605.
10. Deforche K, Silander T, Camacho R, et al.: Analysis of HIV-1 pol sequences using Bayesian networks: Implications for drug resistance. Bioinformatics 2006;22:2975-2979.
11. de Mendoza C, Morelló J, Garcia-Gascó P, Rodríguez-Novoa S, and Soriano V: Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin Pharmacother 2007;8:839-850.
12. De Meyer S, Vangeneugden T, van Baelen B, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24:379-388.
13. Mitsuya Y, Winters MA, Fessel WJ, et al.: N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses 2006; 22:1300-1305.
14. Masquelier B, Breilh D, Neau, Lawson-Ayayi S, et al.: Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitorexperienced patients. Antimicrob Agents Chemother 2002; 46:2926-2932.
15. LatailladeM, Chiarella J, andKozalMJ:Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007;12:563-570.